- The World Health Organization has joined those calling for a reduction in the prices of new Hepatitis C drugs, such as Gilead's (GILD) Sovaldi and Jonhson & Johnson's (JNJ) Olysio. In the U.S., Sovaldi costs $84,000 and Olysio $66,000.
- Around 150M people worldwide suffer from chronic hepatitis C, but the vast majority live in poor countries that can't afford the price.
- Pharmaceutical companies could follow the model that was used to bring the cost of HIV treatments down in the developing world, and Gilead is already giving Egypt a 99% discount on Sovaldi.
at Zacks.com (Nov 17, 2014)